Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ALK S1206Y ALK rearrange||lung non-small cell carcinoma||resistant||Crizotinib||Case Reports/Case Series||Actionable||In a clinical case study, a non-small cell lung cancer patient harboring an ALK rearrangement responded to Xalkori (crizotinib) therapy, but then progressed after 32 months, and was found to have acquired ALK S1206Y (PMID: 25724526).||25724526|
|ALK S1206Y ALK rearrange||lung non-small cell carcinoma||resistant||Crizotinib||Preclinical - Cell culture||Actionable||In a preclinical study, transformed cells expressing ALK S1206Y in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).||22277784|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|